Dr. Daniel J. Salzberg, M.D., F.A.C.P. is an Assistant Professor of Medicine in the Division of Nephrology. He received his medical degree from Albert Einstein College of Medicine, where he was elected into the Alpha Omega Alpha Honor Society. He completed his Internal Medicine and Nephrology training at the premier military hospital, Walter Reed Army Medical Center. Dr. Salzberg then served as the Assistant Chief of Nephrology and the Medical Director of Dialysis at Brooke Army Medical Center in Texas, before joining the faculty at the University of Maryland in 2000. As a clinician educator, Dr. Salzberg has served as the Nephrology Fellowship Program Director, and is actively involved with teaching Fellows, Residents, and Medical Students. Given his dedication to patient care and humanitarianism, he was inducted into the Humanism Honor Society.
Dr. Salzberg’s primary research has focused on proteinuric kidney disease, specifically exploring the use of RAAS blockade in subjects who have had a kidney transplant. Consequentially, he has been an invited lecturer on this topic at both local and national meetings.
In addition to his interest in research, Dr. Salzberg is a clinician educator, and is currently the third-year Medicine clerkship assistant director. He is actively involved in teaching and developing educational curriculum / material for the Renal Physiology course for both first and second year medical students. Dr. Salzberg received numerous accolades during his 10 year appointment as the Nephrology Fellowship Program Director. He is noted to be an exceptional educator, has won numerous teaching awards, and is a much sought after lecturer.
Dr. Salzberg has a special interest in Transplant Nephrology, Dialysis, and ICU Nephrology. He is currently the assistant Medical Director at the IDF Parkview Dialysis Center, and frequently attends on the General Medicine Service, ICU Nephrology Service, and the Nephrology Consultation Service.
Salzberg DJ: Is RAS blockade routinely indicated in hypertensive kidney transplant patients? Curr Hypertens Rep. 2007 Nov;9(5):422-9. PMID: 18177591
Akinbamowo AO, Salzberg DJ, Weir MR. Renal Consequences of Prostaglandin Inhibition in Heart Failure. Heart Failure Clin 4, 2008, pp 505-510. PMID:18760760
Salzberg DJ, Weir M: Recent transplant issues in hypertension. pp 227-242. Ed Raymond Townsend, The Year in Hypertension, Volume 7 (published 4Jan08) ISBN: 184692023X
Salzberg DJ: Quality of life in dialysis patients. pp 570-584. Principles and Practices of Dialysis, Ed William Henrich, MD, 4th edition, Lippincott Williams & Wilkins (published 2009) ISBN: 978-0-7817-8163-3
Weir MR, Salzberg DJ: Management of hypertension in the transplant patient. J Am Soc Hypertens. 2011 Sep-Oct;5(5):425-32. PMID:21925458
Brown EM, Salzberg DJ, and Weir MR. Renal Consequences of Prostaglandin Inhibition in Heart Failure, The Kidney in Heart Failure 2012, Part 3, 117-125, DOI: 10.1007/978-1-4614-3694-2_9
Salzberg DJ, Hanes D: Quality of life in dialysis patients. pp 556-569. Principles and Practices of Dialysis, Ed William Henrich, MD, 3rd edition, Lippincott Williams & Wilkins (published 1Sep03) ISBN: 0781738814
Salzberg DJ, Hanes DS, Cangro CB: Medical complications of the eyes, nasopharynx, dentition, oropharynx and hearing in the kidney transplant recipient. Medical Management of Kidney Transplantation, Ed Matthew R. Weir, © 2005 Lippincott Williams & Wilkins
Salzberg DJ, Weir MR: The kidney and rheumatological diseases. pp 297-314. Rheumatology, 4th Edition, Ed Marc C. Hockberg (published 2007) ISBN: 0323033644
Salzberg DJ, Weir MR. COX-2 inhibitors and cardiovascular risk. Subcell Biochem. 2007; 42:159-74. PMID: 17612050 (Inflammation in the Pathogenesis of Chronic Disease, Volume 42, Chapter 7 Ed: Randall E. Harris, Springer)
Hepburn MJ, Battafarano DF, Enzenauer RJ, Salzberg DJ, Murphy FT, Parisek RA, Kroenke K. Increasing resident research in a military internal medicine program. Mil Med. 2003 Apr;168(4):341-5. PMID: 12733683
Lu WX, Jones-Burton C, Zhan M, Salzberg DJ, Moore J Jr, Fink JC. Survival benefit of recombinant human erythropoietin administration prior to onset of end-stage renal disease: variations across surrogates for quality of care and time. Nephron Clin Pract. 2005;101(2):c79-86. Epub 2005 Jun 20. PMID: 15976508
Salzberg DJ, Weinstein AJ: Web Alert, Current Hypertension Reports, Vol 8, No 1 (Apr 2006), pp. 1-2, ISSN: 1522-6417
Salzberg DJ, Weinstein AJ: Web Alert, Current Hypertension Reports, Vol 8, No 2 (May 2006), pp. 103-105
Salzberg DJ, Weinstein AJ: Web Alert, Current Hypertension Reports, Vol 8, No 3 (June 2006), pp. 181-182
Salzberg DJ, Weinstein AJ: Web Alert, Current Hypertension Reports, Vol 8, No 4 (July 2006), pp. 271-272
Salzberg DJ, Weinstein AJ: Web Alert, Current Hypertension Reports, Vol 8, No 6 (Dec 2006), pp. 437-438
Armentano MJ, Brenner AK, Hedman TL, Solomon ZT, Chavez J, Kemper GB, Salzberg D, Battafarano DF, Christie DS. The effect and safety of short-term creatine supplementation on performance of push-ups. Mil Med. 2007 Mar;172(3):312-7. PMID: 17436778